Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Pharmaceutical Industries Ltd.

https://www.tevapharm.com/

Latest From Teva Pharmaceutical Industries Ltd.

Stick, Twist Or Split? Generics Industry’s Big Three Place Their Bets

With Teva and Viatris recently under new management and Sandoz having last year split from former parent company Novartis, the three off-patent industry leaders are adopting different strategies for how they balance their generics and biosimilars interests with more innovative ventures. Generics Bulletin takes a look at the bigger picture.

Strategy Leadership

ADHD Drugs: FDA Commissioner Blames Inappropriate Prescribing For Shortages

ADHD drug shortages may have resulted from industry reticence to fill DEA quotas, as well as a 'heavy element of professional responsibility' with off-label prescribing, Robert Califf told a House appropriations subcommittee.

Supply Chain Manufacturing

The Comeback Begins? Positive Signs Seen For Humira Biosimilars In US

After getting off to a slow start last year, US biosimilar rivals to Humira are beginning to gain more traction. Sandoz is increasing its share on a weekly basis, Alvotech and Teva have struck a deal for their newly-approved interchangeable 100mg/ml biosimilar, and the latest market data shows biosimilars capturing twice as much of the market in Q1 as in Q4 2023.

Biosimilars United States

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.

Biosimilars Commercial
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Other Names / Subsidiaries
    • ABIC Marketing Limited
    • AbZ-Pharma
    • Auspex Pharmaceuticals, Inc. (Imphar AG)
    • Barr Pharmaceuticals
    • Bentley Pharmaceuticals
    • BioGeneriX AG
    • BioAssets Development Corporation
    • Cephalon, Inc. (Arana Therapeutics (Peptech and EvoGenix)
    • Ception Therapeutics
    • ChemGenex Pharmaceuticals Limited
    • CIMA Labs
    • Gemin X Pharmaceuticals
    • CT Arzneimittel GmbH
    • Gecko Health Innovations
    • IVAX Corporation
    • Labrys Biologics
    • Mepha
    • MicroDose Therapeutx Inc.
    • Neose Technologies, Inc.
    • NuPathe, Inc.
    • PLIVA HRVATSKA d.o.o.
    • ratiopharm Group
    • Sicor Biotech
    • Representaciones e Investigaciones Médicas, S.A. de C.V.
    • Taiyo Pharmaceutical Industry Co. Ltd.
    • Teva Branded Pharmaceutical Products, R&D Inc.
    • Teva Women's Health, Inc.
    • Actavis Generics
    • Anda, Inc.
    • Uteron Pharma S.P.R.L.
    • Teva Takeda Yakuhin Ltd.
    • Teva Takeda Pharma Ltd.
    • Teva Neuroscience, Inc.
    • Teva Pharmaceuticals USA, Inc.
    • Zeneus Pharma
UsernamePublicRestriction

Register